<code id='39FC0E901E'></code><style id='39FC0E901E'></style>
    • <acronym id='39FC0E901E'></acronym>
      <center id='39FC0E901E'><center id='39FC0E901E'><tfoot id='39FC0E901E'></tfoot></center><abbr id='39FC0E901E'><dir id='39FC0E901E'><tfoot id='39FC0E901E'></tfoot><noframes id='39FC0E901E'>

    • <optgroup id='39FC0E901E'><strike id='39FC0E901E'><sup id='39FC0E901E'></sup></strike><code id='39FC0E901E'></code></optgroup>
        1. <b id='39FC0E901E'><label id='39FC0E901E'><select id='39FC0E901E'><dt id='39FC0E901E'><span id='39FC0E901E'></span></dt></select></label></b><u id='39FC0E901E'></u>
          <i id='39FC0E901E'><strike id='39FC0E901E'><tt id='39FC0E901E'><pre id='39FC0E901E'></pre></tt></strike></i>

          Home / comprehensive / leisure time

          leisure time


          leisure time

          author:comprehensive    Page View:9
          Novo Nordisk Denmark
          LISELOTTE SABROE/AFP/Getty Images

          A pill being developed by Danish drugmaker Novo Nordisk may lead to greater weight loss than the obesity therapy Wegovy, the company reported Thursday, citing early data.

          In a Phase 1 trial, participants experienced an average of 13.1% weight loss after 12 weeks of taking the experimental oral medicine amycretin, according to data presented at an investor meeting. In comparison, in an earlier Phase 3 trial of the injectable drug Wegovy, people taking Wegovy lost about 6% of their body weight over the same time period.

          advertisement

          Novo Nordisk has been on a mission to capitalize on its success with Wegovy, which brought in $4.5 billion in sales last year. (The drug is also sold as a diabetes treatment under the name Ozempic. That version of the drug brought in another $14 billion in sales).

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In